Proportion of Days Covered: Renin Angiotensin System Antagonists (PDC-RASA)

Star Measure: Medication Adherence Hypertension (RAS antagonist)

By working together, we can improve health outcomes for your patients, our members. Pharmacy Quality Alliance (PQA) measures are included in the Centers for Medicare and Medicaid Services’ (CMS) Stars program which is used to assess Medicare Part D prescription drug plans quality and performance. Adherence measures are developed by PQA and endorsed by the National Quality Forum. This tip sheet provides key details of the adherence measure for Proportion of Day Covered: Renin Angiotensin System Antagonists (RASA).

What is the measure?

This measure analyzes the percentage of Medicare Part D beneficiaries, 18 years or older, with a proportion of days covered (PDC) of 80% or higher for hypertension medications in targeted drug class(es) (renin-angiotensin system (RAS) antagonists, during the measurement period. The measurement period is limited to a single contract year.

Note: The PDC is the percent of days in the measurement period covered by prescription claims for the same medication or another in its therapeutic category.

Exclusions

- One or more prescriptions for sacubitril/valsartan
- Diagnosis of end-stage kidney disease
- Member in hospice

Denominator

Eligible population: Members enrolled in Medicare Part D, 18 years and older who filled at least two prescriptions for any RASA or RASA combination product on different dates of service during the measurement period.

- Members qualify for the measure with the second fill, but the adherence measurement episode starts with the date of the first fill and ends with an enrollment gap, death, or the measurement period end date.
- The first fill of medication must occur at least 91 days before the end of the adherence episode within the measurement period.

Numerator

Eligible members with a proportion of days covered (PDC) of 80% or higher for the targeted drug class(es).

1Healthcare Effectiveness Data and Information Set (HEDIS) is a registered trademark of the National Committee for Quality Assurance. Florida Blue and Florida Blue Medicare are Independent Licensees of the Blue Cross and Blue Shield Association. Copyright 2020/2021 PQA, Inc. All rights reserved. pqaalliance.org.

(continued next page)
Proportion of Days Covered: Renin Angiotensin System Antagonists (continued)

Medication Class

- Angiotensin converting enzyme (ACE) inhibitor
- Angiotensin receptor blocker (ARB)
- Direct renin inhibitor drug

Best Practices to Improve Adherence

- Discuss with members why they are on a specific medication. Reinforce the role and importance of taking their blood pressure medication. Together, identify and resolve member-specific adherence barriers or concerns (health benefits, side effects, timely refills and cost).
- Educate member on taking the medication as directed on the prescription, such as: not to split the pills; not to change dosage frequency.
- Monitor members who are at risk for poor compliance; please reach out prior to refill due date.
- Reach out to your members and advise them to refill their prescription as soon as possible.
- Send updated prescription to the pharmacy for medication or dosage changes. Avoid long gaps in time between the first and second fill.
- If a member is eligible, consider a 90-day supply and switching to generic for improved adherence. Recommend PillPack for patients on complex medication regimens.
- Encourage members to use the automatic refill option and to use our pharmacy mail order service to help with adherence.
- Encourage members to use their Florida Blue Medicare member card at the pharmacy to generate pharmacy claims and capture member compliance.

References

- pqaalliance.org/medicare-part-d